49 Results

People

  1. Postow
    Postow
  2. Wolchok
    Wolchok
  3. Callahan
    Callahan
  4. Shoushtari
    Shoushtari
  5. Betof Warner
    Betof Warner
  6. Panageas
    Panageas
  7. Friedman
    Friedman
  8. Momtaz
    Momtaz
  9. Chapman
    Chapman
  10. Coit
    Coit

Groups

  1. Department of Medicine (49)
  2. Melanoma Disease Management Team (49)
  3. Melanoma and Immunotherapeutics Service (49)
  4. Solid Tumor Oncology Division (49)
  5. GSK Faculty (20)
  6. Hematologic Malignancies, Division of (16)
  7. Survivorship Research (10)
  8. Biostatistics Service (8)
  9. Epidemiology and Biostatistics (8)
  10. Population Sciences Research Program (8)
  1. "nivolumab"
  2. "Michael Postow"
Formats
  1. Journal Article (42)
  2. Review (3)
  3. Editorial (2)
  4. Correspondence (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (49)
  2. Melanoma Disease Management Team (49)
  3. Melanoma and Immunotherapeutics Service (49)
  4. Solid Tumor Oncology Division (49)
  5. GSK Faculty (20)
  6. Hematologic Malignancies, Division of (16)

More Groups

People
  1. Michael Postow (49)
  2. Jedd Wolchok (20)
  3. Margaret Callahan (14)
  4. Alexander Shoushtari (9)
  5. Allison Betof Warner (7)
  6. Katherine Panageas (7)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2022 (7)
  4. 2021 (3)
  5. 2020 (7)
  6. 2018 (8)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (5)
  2. Journal of Clinical Oncology (5)
  3. Cancer (3)
  4. Clinical Cancer Research (2)
  5. European Journal of Cancer (2)
  6. Frontiers in Immunology (2)

More Publications

Publishers
  1. Biomed Central Ltd (6)
  2. American Society of Clinical Oncology (5)
  3. Wiley Blackwell (5)
  4. Elsevier Inc. (4)
  5. Elsevier Science, Inc. (3)
  6. Frontiers Media S.A. (3)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: A systematic review and meta-analysis
    Review

    Sala, I.; Pagan, E.; Pala, L.; Oriecuia, C.; Musca, M.; Specchia, C.; De Pas, T.; Cortes, J.; Giaccone, G.; Postow, M.; more...
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Exocrine pancreatic insufficiency induced by immune checkpoint inhibitors
    Journal Article

    Satish, D.; Lin, I. H.; Flory, J.; Gerdes, H.; Postow, M. A.; Faleck, D. M.
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Recent advances in the field of artificial intelligence for precision medicine in patients with a diagnosis of metastatic cutaneous melanoma
    Review

    Higgins, H.; Nakhla, A.; Lotfalla, A.; Khalil, D.; Doshi, P.; Thakkar, V.; Shirini, D.; Bebawy, M.; Ammari, S.; Lopci, E.; more...
    Diagnostics (2023)

    Fulltext@MSK | Save
  • Eganelisib, a first-in-class PI3Kγ inhibitor, in patients with advanced solid tumors: Results of the phase 1/1b MARIO-1 trial
    Journal Article

    Hong, D. S.; Postow, M.; Chmielowski, B.; Sullivan, R.; Patnaik, A.; Cohen, E. E. W.; Shapiro, G.; Steuer, C.; Gutierrez, M.; Yeckes-Rodin, H.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Neoadjuvant relatlimab and nivolumab in resectable melanoma
    Journal Article

    Amaria, R. N.; Postow, M.; Burton, E. M.; Tezlaff, M. T.; Ross, M. I.; Torres-Cabala, C.; Glitza, I. C.; Duan, F.; Milton, D. R.; Busam, K.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Adjuvant checkpoint blockade following complete local therapy for melanoma metastases
    Editorial

    Smithy, J. W.; Postow, M. A.
    Lancet (2022)

    Fulltext@MSK | Save
  • Standardized guidelines for acral and nail unit melanoma treatment are lacking
    Correspondence

    Falotico, J. M.; Postow, M. A.; Lipner, S. R.
    Journal of the American Academy of Dermatology (2022)

    Fulltext@MSK | Save
  • The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021
    Review

    Ascierto, P. A.; Butterfield, L. H.; Finn, O. J.; Futreal, A.; Hamid, O.; LaVallee, T.; Postow, M. A.; Puzanov, I.; Sosman, J.; Fox, B. A.; more...
    Journal of Translational Medicine (2022)

    Fulltext@MSK | Save
  • Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
    Journal Article

    Ghosh, N.; Postow, M.; Zhu, C.; Jannat-Khah, D.; Li, Q. Z.; Vitone, G.; Chan, K. K.; Bass, A. R.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save